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Summary of Progress 
 The specific aims of this project can be summarized as follows: 
 
• Aim 1:  Prepare and evaluate radiolabeled ligands for the peroxisome proliferator-activated receptor γ 
(PPARγ), a new nuclear hormone receptor target for tumor imaging and hormone therapy. 
• Aim 2:  Prepare steroids labeled with a cyclopentadienyl tricarbonyl technetium or rhenium unit.  
• Aim 3:  Prepare and evaluate other organometallic systems of novel design as ligand mimics and 
halogenated ligands for nuclear hormone receptor-based tumor imaging. 
 
 As is described in detail below, we made excellent progress on all three of these aims; the highlights of 
our progress are the following:  
• we have prepared the first fluorine-18 labeled analogs of ligands for the PPARγ receptor and used 
these in tissue distribution studies in rats 
• we have developed three new methods for the synthesis of cyclopentadienyltricarbonyl rhenium and 
technetium (CpRe(CO)3 and CpTc(CO)3) systems and we have adapted these to the synthesis of 
steroids labeled with these metals, as well as ligands for other receptor systems 
• we have prepared a number of fluorine-18 labeled steroidal and non-steroidal androgens and measured 
their tissue distribution in rats 
• we have prepared iodine and bromine-labeled progestins with high progesterone receptor binding 
affinity 
• we have prepared inorganic metal tricarbonyl complexes and steroid receptor ligands in which the 
metal tricarbonyl unit is an integral part off the ligand core.  
 
 Throughout the detailed description of our past progress, reference is made to publications that have 
arisen from each section as ["Pub. No. (#)"].  Reference is made only to the refereed papers [1–36], which are 
listed in the end of this report. 
 
 
 
Detailed Final Report 
 
1.  Progress Under Previous Aim 1: Prepare and evaluate radiolabeled ligands for the peroxisome 
proliferator-activated receptor γ (PPARγ), a new nuclear hormone receptor target for tumor 
imaging and hormone therapy. [Pub. No. 18, 33, 34].  
 
 Because it is believed that the PPARγ receptor may be a good target for imaging small metastatic 
tumors, we first undertook the synthesis of two representative, high affinity PPARγ ligand in fluorine-18 
labeled form (9 and 22, Scheme 1, left).  The parent compound is known to have high affinity ligand for 
PPARγ, and the synthesis of precursors suitable for labeling these two analogs with fluorine-18 proceeded 
uneventfully, although it was a challenging, multistep synthesis.   
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Scheme 1.  Fluorine-Substituted PPARγ Ligands Synthesized (left) and for Possible Further Consideration (right). 
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 One of the fluorine-substituted products (22) was found to have relatively high affinity for PPARγ, at 
least in the low nanomolar range (7 nM), comparable to that of the parent ligand, and we prepared this analog 
in fluorine-18 labeled form in reasonable yield and at sufficiently high specific activity to conduct tissue 
distribution studies in rats and in mice bearing human breast tumor xenografts.  We looked for selective 
accumulation in normal tissues and tumors that are known to contain PPARγ, but we did not find significant 
selective uptake in these tissues, and no tissue showed uptake that could be blocked by coadministration of a 
blocking dose of unlabeled ligand.   
 In evaluating our experience with these PPARγ ligands, we recognize that this target system presents 
two special challenges for imaging, low receptor density and unusual ligand pharmacology.  First, the 
concentration of this receptor, even in the richest tissues, is considerably lower than that of the steroid 
receptors.  Thus, in order to image this receptor effectively, one would need a ligand with exceedingly high 
affinity and high specific activity.  Since we initiated this project, higher affinity PPARγ ligands such as GI 
262570 (Scheme 1, right; Kd = 0.34 nM) have been reported.70  This compound forms the basis of a new series 
of radiohalogenated ligands that we plan to investigate for the PPARγ target.  The second challenge is 
pharmacokinetic: most of the potent PPARγ ligands are lipophilic acids that are highly bound to serum 
proteins and have long clearance times.   
 We prepared several new PPARγ ligands based on the GI262570 structure; the structures of two of 
these are shown in Scheme 2.  Our selection of the site of halogen substitution (X) is based a site known to be 
tolerant of substitution in this ligand series.  Our synthesis of compound 2 was patterned after that described in 
the literature by the Glaxo-Wellcome group and is shown in Schemes 3 and 4. 
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Scheme 2.  Two new Radiohalogenated PPARγ Ligands 
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aReaction conditions: (i) aniline, pyridine, rt, 12 h; (ii) 1) POCl3, N,N-dimethylaniline, 150 oC, 4 h, 2) 
50% aq. HCl, 100 oC, 2 h; (iii) fluorobenzene, AlCl3, FeCl3, rt, 20 h; (iv) CF3SO2OCH3, CH2Cl2, rt, 12 h; 
(v) TBAF, CH3CN, 90 oC 1 h. 
Scheme 3. Synthesis of the benzophenone portion of PPARγ ligand 1. 
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 4
aReaction conditions: (i) 2-(5-methyl-2-phenyloxazol-4-yl)ethanol, PPh3, DEAD, THF, 0 oC ~ rt, 12 h; (ii) 
TFA/CH2Cl2, rt, 6 h; (iii) 13, K2CO3, CuI, DMF, 90 oC, 4 h. 
Scheme 4. Completion of the synthesis of the PPARγ ligand 1. 
 
 The other PPARγ ligand based on GI262570 are shown in Scheme 5 below; in addition to the fluoro 
analog, there are bromine and iodine analogs.  
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Scheme 5.  Other new Radiohalogenated PPARγ Ligands 
 
 Synthesis of these three ligands in unlabeled form is given in Scheme 6 below. The synthesis designed 
for radiobromination or radioiodination proceeds through the aryl tin intermediate, shown in Scheme 7, and 
the route suitable for radiofluorination proceeds through a diaryliodonium salt, as shown in Schemes 8 and 9, 
below. 
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aReaction conditions: (i) 4-halobenzamide, 1,2-dichlorobenzene, 130 °C, 24 h; (ii) LAH, THF, 0 °C, 1 h, or NaBH4, 
MeOH, rt, 6 h; (iii) PPh3, DEAD, THF, 0 °C ~ rt, 12 h; (iv) LiOH, THF/MeOH, rt, 6 h. 
Scheme 6.  Synthesis of three new halogenated PPARγ Ligands in unlabeled form 
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aReaction conditions: (i) (PPh3)4Pd, Sn2Bu6, Toluene, 120 °C, 12 h; (ii) (a) NH4Br, CH3CO3H, 
CH3COOH, rt, 30 min, (b) LiOH, THF/MeOH, rt, 1 h.; (iii) (a) NaI, CH3CO3H, CH3COOH, rt, 30 min, 
(b) LiOH, THF/MeOH, rt, 1 h. 
Scheme 7.  Synthetic sequence suitable for radiobromination and radioiodination of PPAR γ Ligands . 
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aReaction conditions: (i) Various Koser reagents, CH2Cl2, rt, 12 h. 
 
Scheme 8.  Synthesis of diaryliodonium salt precursor for F-18 labeling of PPAR γ Ligands . 
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Scheme 9.  Reaction of diaryliodonium salt precursor for F-18 labeling of PPAR γ Ligands . 
 
 One of these new PPARγ ligands was labeled with F-18, as shown in Scheme 10. Tissue distributions 
done in Sprague-Dawley rats (Tabl 1) showed pronounced uptake in brown fat, the tissue in non-tumor 
bearing animals that is highest in PPARγ. Uptake in brown fat also could be blocked by coadministration of a 
high dose of unlabeled compound, further suggesting that the uptake in this tissue is due to PPARγ. 
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Reaction condition: (i) K+18F-, Kryptofix,  MeCN, 110 oC, 10 min; (ii) 
tetrabutylammonium hydroxide (40% aqueous solution); (iii) [18F]benzophenone, 
CuI, DMF, N2, 130 oC, 20 min.  
Scheme 10.  F-18 labeling of a PPAR γ Ligands. 
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TABLE 1. Biodistribution of [18F]1 in Normal Mautre Female Sprague-Dawkey Rats 
Mean percentage injected dose per gram + SD (n = 5)  
Tissue/organ 1 h 1 h (blocked) 2 h 2 h (blocked) 
Blood 0.07 + 0.01 0.05 + 0.02 0.04 + 0.01 0.04 + 0.01 
Lung 0.06 + 0.01 0.06 + 0.01 0.04 + 0.02 0.04 + 0.01 
Liver 11.52 + 3.80 8.36 + 2.21 6.28 + 1.89 5.51 + 1.91 
Spleen 0.13 + 0.03 0.13 + 0.03 0.07 + 0.03 0.10 + 0.04 
Kidney 0.17 + 0.05 0.14 + 0.03 0.09 + 0.02 0.08 + 0.02 
Muscle 0.04 + 0.01 0.03 + 0.01 0.02 + 0.00 0.01 + 0.00 
White Fat 0.05 + 0.02 0.02 + 0.01 0.01 + 0.00 0.01 + 0.00 
Brown Fat 0.13 + 0.01 0.07 + 0.01 0.12 + 0.03 0.08 + 0.01 
Heart 0.07 + 0.01 0.06 + 0.02 0.04 + 0.01 0.04 + 0.01 
Bone 0.04 + 0.01 0.04 + 0.01 0.03 + 0.00 0.03 + 0.01 
 
2.  Progress Under Previous Aim 2: Develop methods for labeling small molecules with a 
cyclopentadienyl tricarbonyl technetium or rhenium unit. [Pub. No. 1, 2, 4, 5, 7-9, 11-15, 20, 25, 26]  
 In our previous application, we reported that certain steroids containing a cyclopentadienyl tricarbonyl 
rhenium group (CpRe(CO)3) appeared to be promising ligands for receptors.  This organometallic function 
provides a novel means of incorporating rhenium (CpRe(CO)3) and technetium (CpTc(CO)3) into small 
organic molecules via chemical linkages that are small, non-polar and very stable.  Despite the unique 
structural features of the CpRe(CO)3 and CpTc(CO)3 groups and their promise for radiolabeling, what had 
been missing was an effective method for preparing these systems efficiently and conveniently at the tracer 
level and at high specific activity.  Most known preparations of these systems utilized slow reactions that 
proceeded under awkward conditions—involving autoclaves to contain high pressures of carbon monoxide—
to reduce pertechnetate or perrhenate to the dimetal decacarbonyl state, from which the pentacarbonyl bromide 
is prepared and then reacted with the Cp anion. During the past project period, we have developed three new 
methods for preparing the CpMet(CO)3 system conveniently and efficiently.   
 
2.a.  Double Ligand Transfer (DLT) Reaction – We have successfully adapted an unusual ligand 
transfer process termed the "central atom exchange" reaction or the "double ligand transfer" (DLT) reaction 
for the preparation of CpRe(CO)3 or Tc-99m labeled CpTc(CO)3 at high specific activity.  During this 
exchange reaction, shown in Scheme 11, pertechnetate or perrhenate is reduced by Cr(III) in the presence of a 
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source of CO (Cr(CO)6) and a Cp donor (bis-methoxycarbonylferrocene, 13).  Although the reaction requires 
high temperatures, it can be performed conveniently in a sealed tube, and good yields are obtained; in fact, 
higher yields are obtained with Tc-99m at the tracer level than with larger quantities of Re and Tc-99.  The 
modifications of this central atom exchange reaction that we have made avoid the use of manganese 
carbonyls, which was an essential component of the original description of this reaction.  The use of 
manganese carbonyls resulted in the production of CpMn(CO)3, which proved difficult to separate from the 
CpRe(CO)3 and CpTc(CO)3 products, greatly reducing the effective specific activity of the Tc-99m 
compound.  The only limitation on this reaction is that exchange occurs readily only when the ferrocene 
system is substituted with electron withdrawing groups.  These groups appear to provide the needed 
labilization of the Cp system required for transfer from the Fe to the Tc or Re centers.   
 
Re
OC
CO
CO
Fe + KReO4 Cr(CO)6+
Methanol
150ÞC, 1 hr 
      53%
CO2Me CO2Me
CrCl2+
1413
CO2Me
 
Scheme 11. Modified Double Ligand Transfer Reaction that Gives High Effective Specific Activity 
 
 With support from this project, we have demonstrated the utility of this reaction for labeling various 
receptor ligands with Tc-99m; these are described below.  Initially, we did this through a CpTc(CO)3 active 
ester, which could readily be prepared using the DLT reaction; we also labeled molecules with ferrocene 
precursors having ketone linkages.  However, despite the success we had with the DLT in a number of 
systems, we recognized the need to expand methods for the preparation of CpTc(CO)3 and CpRe(CO)3 
systems.  We explored a number of alternative approaches and have found two new methods that provide a 
great expansion of methods for the preparation of these CpMet(CO)3 systems that can be used for 
radiolabeling with short-lived isotopes: the three-component condensation and the Cp-tin transfer reactions.  
These two new methods are discussed in the sections below. 
 
2.b.  Three-Component Condensation  – Hermann had shown that CpTc(CO)3 systems could be 
prepared by reaction of diazocyclopentadiene with bromotechnetium pentacarbonyl.  This was a sluggish 
reaction that had the additional disadvantage that it gave only the product having a bromine substituent on the 
Cp ring, that is, the halogen nucleophile that was prebound by the metal became incorporated in the carbon 
skeleton.  We reasoned that if we removed this halogen from the metal precursor, then we might be able to 
introduce a variety of exogenous nucleophiles and have them become incorporated in the Cp ring.  Indeed, we 
found that by replacing BrTc(CO)5 with the Re(CO)3+ or Tc(CO)3+, cations in which the halogen had been 
removed using silver triflate, we could introduce other nucleophiles (Scheme 12).  The nucleophiles that 
worked best were carboxylates, which gave as products acyloxyCpMet(CO)3 (Scheme 3, left), and boronic 
acids, which gave aryl and vinyl CpMet (CO)3 systems (Scheme 3, right). 
R C
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R C
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+"
R B
OH
OH
M(CO)3
R
N2
CH3CN
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Scheme 12.  Three-Component Condensation to Prepare Acyloxy and Aryl/Vinyl CpMet(CO)3 Systems 
 
 The three-component condensation works under very mild conditions and proceeds in good yields.  
Examples of both types of this reaction are given in Table 2 below, and the technetium and rhenium 
organometallic structures that we can produce by this method are more complex than any hithertofore 
prepared.  Additional examples are given below.  The acyloxy-CpMet(CO)3 systems can be considered the 
“carboxy-inversion analogs” of the CpMet(CO)3 carboxylates that come from the DLT reaction.  The ester 
link to the Cp phenol is rather stable.  The vinyl and aryl-substituted systems are novel. 
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Table 2. Structures and Isolated Yields in the Three-Component Condensation with Various Cyclopentadienes  
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 Because this is an unusual transformation, we examined its mechanism in some detail.  Through a 
combination of spectroscopic examinations of reaction intermediates, using FT-IR and NMR with C-13 
labeled precursors, as well as a linear free energy study of various para-substituted carboxylates, we were able 
to conclude that the reaction proceeds in the following fashion: As illustrated in Scheme 13, there is an initial 
interaction between the metal and the nucleophile (i.e., carboxylate oxygen or boronic acid oxygen); the diazo-
substituted carbon then interacts with the metal center; there is then a synchronous transfer through a multi-
center transition state of the metal-bound nucleophile (i.e., oxygen in the case of carboxylate nucleophiles or 
aryl or vinyl group in the case of the boronic acids) to this center with loss of nitrogen, and finally, the initial 
η1-Cp product isomerizes to the η5-Cp product (the latter isomerization not shown).   
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Scheme 13.  Transition State for the Three-Component Condensation with Carboxylates and Boronic Acids. 
 
 The critical component of this reaction is diazocyclopentadiene, a molecule that is easy to prepare but 
is unstable on storage and potentially explosive, clearly undesirable characteristics for general synthesis and 
particularly for routine radiochemical preparations that might be done by medical technicians.  We found, 
however, that the stable, crystalline adduct of diazocyclopentadiene and triphenylphosphine works just as well 
in the three-component condenstation as does diazocyclopentadiene itself.  Furthermore, this adduct can be 
prepared from triphenylphosphine tethered on a solid support.  This provides the added convenience of 
removing from the reaction product any phosphorous-containing material. 
 The three-component condensation greatly expands the scope of CpMet(CO)3 systems that can be 
prepared, but it is still limited to molecules with a single substituent on the Cp ring.  Therefore, we sought yet 
another method that would be applicable to the preparation of multiply substituted systems.   
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 2.c.  Cp-Tin Transfer Reaction  – We were aware that it is possible to prepare CpTc(CO)3 and 
CpRe(CO)3 systems directly by the reaction of various Cp donors and the technetium and rhenium carbonyl 
cations.  Typically, the Cp thallium salts are used.  We were, however, more intrigued by the use of Cp tin 
systems as donors, because these seemed to proceed under mild conditions.  In fact, as shown in Scheme 14, 
we found that a variety of Cp-tin systems, which can be prepared simply by the reaction of cyclopentadiene 
with a tributyltin amide, worked as excellent Cp transfer agents, reacting readily with metal carbonyl 
precursors.  The reaction with the rhenium tricarbonyl cation, in particular, was very fast.  These reactions do 
not require that halogen be removed from the tricarbonylmetal cation precursor, and they proceed even more 
rapidly and under milder conditions than the three-component condensation.  In addition, we found that 
formation of the Cp-tin intermediate and the Cp transfer to the tricarbonyl metal center could be done in one 
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pot, under aprotic conditions in THF as solvent and the THF-soluble precursor 3.  The yields in the one-pot 
protocol are not high, but the conversion is very convenient.  Thus, we have developed a very general method 
for the synthesis of both singly and multiply substituted CpMet(CO)3 systems.  Examples of this are shown in 
Table 3.  It is of note that, though a collaboration with Radiotracer, Inc., we have used this method to prepare 
some CpMet(CO)3 tropane systems as ligands for the dopamine transporter.   
Re(CO)3
Me3Sn SnBu3BrRe(CO)5 (Et4N)2[ReBr3(CO)3] 1
THF, ↑↓
6 h, 88%
THF/ACN, RT
5 min, 80%
2
Re(CO)3
cyclopenadiene,
Bu3Sn-NEt2, THF
↑↓, 2 h, 28%
indene,
Bu3Sn-NEt2, THF
↑↓, 2 h, 30%
[(THF)BrRe(CO)3]2 
3 Re(CO)3  
Scheme 14. Cp-Tin Transfer Reaction According to the Two-Step Protocol (top) and One-Pot Protocol (bottom). 
Table 3. Structures and Isolated Yields in the Reaction of 3 with Various Cyclopentadienes and Indene 
Entry Reactant Yield 
(%) Product
 
1 
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3.  Progress Under Previous Aim 3: Prepare and evaluate metal complexes and organometallic systems 
of novel design as ligand mimics and analogs for nuclear hormone receptor-based tumor imaging [Pub. 
No. 3, 6, 10-12, 15, 16] 
 
3.a.  Synthesis of Integrated Oxotechnetium Amino-Thiol Complexes that Mimic Steroids. – Prior to 
the last period of funding, it appeared that it might be possible to prepare integrated inorganic oxotechnetium 
amino-thiol complexes that would effectively mimic not only the geometry of steroids but the receptor binding 
affinity properties of these hormones as well.  The syntheses of these systems proved to be a formidable 
challenge at which we ultimately succeeded.  However, despite our considerable efforts, we were unable to 
obtain any integrated N2S2 bis-bidentate or related tetradentate chelate system that demonstrated the proper 
combination of sufficient stability and significant receptor binding affinity.  Nevertheless, despite our lack of 
biological success in this endeavor, through this work we did expand our chemical facility for the preparation 
of these metal complexes. 
 Because of the success that others had achieved in the synthesis of stable 3+1 oxotechnetium amino-
thiol complexes,77 we undertook the preparation of a series of 3+1 complexes whose shape mimicked that of 
non-steroidal ligands for the estrogen receptor.  (Estrogens were prepared for simplicity, to evaluate feasiblity 
of preparing the synthetically more complex androgens and progestins.)  The complexes were patterned after 
the shape and size of the non-steroidal receptor ligands, hexestrol and tetrahydrochrysenediol.  The structure 
of the best of these complexes is shown in Scheme 15. 
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Hexestrol Tetrahydrochrysene3 + 1 Complex  
 
Scheme 15.  3 + 1 Integrated NS3 Complex (center) and its Parent Ligands (left and right) 
 
 The 3 + 1 complex was quite stable, and by NMR analysis, we found that the unusual tridentate 2,6-
bis(mercaptomethyl)pyridine ligand adopts a non-symmetrical twisted geometry that makes the methylene 
groups non-equivalent, but becomes fluxional at higher temperatures.  However, despite their interesting 
structure, these 3+1 complexes did not have significant affinity for the estrogen receptor, so the further effort 
required to prepare analogs that might bind to androgen and progestin receptors was not deemed worthwhile. 
 
3.b..  Synthesis of Steroids Labeled with Technetium and Rhenium in a Pendant Fashion.  – With 
support of this project and through a collaboration with the radiopharmaceutical group at Rossingdorf, 
Germany, we have prepared and examined the stability and receptor affinity of a number of steroids onto 
which are appended a variety of rhenium and technetium complexes, notably tetradentate 3+1 
oxotechnetium/rhenium(V) complexes, and also derivatives of technetium/rhenium in other oxidation states, 
such as pentadentate technetium/rhenium (III) isonitrile complexes, dithioether-halide complexes of 
tricarbonyltechnetium/rhenium (I), and cyclopentadienyltricarbonyltechnetium/rhenium (I).  The structures of 
these “pendant” complexes and the routes used for their preparation are summarized below in Schemes 7-9. 
The first series we prepared were progestins complexes labeled at the C-21 position with a set of 
rhenium complexes that were attached through a thiol (for oxo-Re(V) 3+1 complexes), an isonitrile (for a 
pentadentate Re(III)-isonitrile complex), a dithioether (for a tricarbonylrhenium(I) bromide complex), and an 
oxygen (for a carbonyl-linked CpRe(CO)3 complex) (Scheme 16).  We could obtain these complexes in good 
yield and in pure form for binding affinity measurements, and, in fact, some of them showed good affinity for 
the progesterone receptor.  However, the highest affinity analogs were the 3+1 complexes in which the steroid 
was attached to the monodentate component.  Considering the results of ligand challenge assays recently 
developed by the Rossindorf group, it is likely that under the conditions of the binding assay the metal center 
dissociated from this thiolate ligand, so what was being measured was the relatively high affinity of the steroid 
free thiol, not the complex itself.  However, the more stable isonitrile and CpRe(CO)3 complexes did show 
significant affinity.  The low overall affinity of these complexes might be ascribed to the C-21 not being the 
most favorable site for substitution on progestins.   
 
S
O
X
O
x =
x =
x =
x =
Re(CO)3O
O
S S Me
ReOC
OC CO
Br
N C Re N
S
S
S
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S
S
S
O
S
Re
S
S
N-Me
O
x =
RBA = 4.7
R5020, RBA = 100
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X = H, RBA = 13
RBA = 9.0
RBA = 1.5
RBA = 0.02
RBA = 2.2
 
 
Scheme 16.  C-21 Conjugates of Progesterone and Rhenium Chelates and Organometallics 
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 The second series of steroids labeled with rhenium/technetium in a pendant fashion were estrogens 
(again for chemical simplicity) labeled at the 7α position with the same set of complexes (Scheme 17).  The 
7α position was selected because it is known that estrogens can be substituted with long chains (up to 15 
atoms long) at this position with preservation of binding affinity.78  As before, we tend to discount the high 
affinity of the 3+1 complexes because of the tendency of these complexes to dissociate under the assay 
conditions.  On the other hand, the other three types of complexes, the isonitrile, the bisthioether and the 
CpMet(CO)3 complex all showed very favorable affinities.  We were particularly encouraged by the high 
affinity shown by the rhenium CpMet(CO)3 complex with the amide link, which showed an affinity that was 
John A. Katzenellenbogen 
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ca. 30% that of the parent ligand!  These results certainly validated our selection of the 7α position as a 
preferred site for tethering a bulky substituent to this steroid ligand.  
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HO
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x =
Re(CO)3O
O
S S M e
ReOC
OC CO
B r
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S
S
S
Re
S
S
S
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S
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S
N-Me
O
x =
RBA = 11
Estradiol, RBA = 100
RBA = 10
RBA = 14
RBA = 12
RBA = 5
X
S
Re
S
S
O
Ox =
RBA = 43
x =
Re(CO)3NH
O
RBA = 29  
 
Scheme 17.  7α Conjugates of Estradiol and Rhenium Chelates and Organometallics 
 
 Based on the intriguingly high affinity of the stable CpRe(CO)3 complex, we prepared this derivative 
labeled with Tc-99m (Scheme 18).  In addition, because we had found the octanol-water partition coefficients 
(log Po/w) of these complexes to be very high, we prepared as well, two analogs in which we had introduced 
ether linkages in the chain tethering the CpMet(CO)3 complex to the C-7α position, in an attempt to lower the 
log Po/w values.  In one case, we kept the chain length the same (six atoms to the amine) but introduced a 
single ether, and in the second case, we extended the chain to include three ether functions.  Although each 
substitution of a methylene group by an ether oxygen is predicted to reduce the log Po/w of a compound by 
1.5,16 we found, surprisingly, that the lipophilicity of these new analogs was only marginally reduced from 
that of the parent compound.   
 
HO
OH
X
Tc(CO)3
HN
O HO
OH
O
Tc(CO)3
HN
O
3X = CH2, RBA = 29
X = O, RBA = 35 RBA = 20  
Scheme 18.  7α Conjugates of Estradiol and CpTc(CO)3. 
 
 Nevertheless, we continued in our efforts to prepare these compounds in Tc-99m labeled form, and we 
were successful in this endeavor, so that we were able to conduct tissue distribution studies in immature rats.  
Unfortunately, despite the favorable binding affinity of these analogs for the receptor, we found that all three 
of these compound showed only very modest uptake in the uterus, the primary target tissue for estrogens.  
Very little of this uptake was blocked by the coadministration of unlabeled estradiol.   
Our interpretation of these results is that despite our efforts to increase their polarity, the CpMet(CO)3-
estrogen derivatives are too lipophilic to show favorable receptor-directed tissue distribution properties in 
vivo.  Their high affinity for the receptor can be demonstrated in in vitro assays, where the concentration of 
other proteins that would compete for their binding in vivo is low, but in vivo, extensive protein binding 
hinders their distribution and the cell membrane penetration that is required for their entry into target tissues.  
By reaching this conclusion, we have redirected our efforts towards the design of a technetium-labeled steroid 
receptor ligand to use the organometallic CpT-Met unit as an integral part of the ligand core.  
 
4.  Progress Under Previous Aims 4:  Prepare and evaluate other novel radiolabeled androgens and 
progestins and their analogs [Pub. No. 1, 10, 15-19, 22-24, 27, 29-32, 35, 36]  
 
4.a.  Synthesis of gallium-substituted analogs of nuclear hormone receptor ligands  – Gallium 
radioisotopes hold considerable promise for the development of diagnostic imaging agents.  Rather than using 
the gallium(III) ion, which requires hexacoordinate chelation to form stable complexes, we have worked with 
the dimethylgallium cation that forms tetravalent complexes that are stable in water.  The tetrahedral geometry 
of these complexes makes them close structural analogs of a tetrahedral carbon.  This affords interesting 
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structural opportunities for the preparation of metal-containing ligands that mimic the structure of ligands for 
nuclear hormone receptors.   
 Previously, we prepared two types of dimethylgallium compounds (Scheme 19).  The first was an 
integrated complex in which the dimethyl gallium unit substituted for an isopropyl group (20), and in the 
second, a dimethylgallium salicylaldimine system was a pendant substituent on a non-steroidal estrogen (22).  
However, we found that neither system was sufficiently stable in water.   
O CH3
O
N
HO
CH3
O
Ga
N
CH3
O
N
HO
CH3
Dimethylgallium Analog ( 20)Centchromene ( 19)
O
Ga
N
H
CH3
R
CH3
21a  (R = n-C6H13) 
21b  (R = n-C10H21)
CH3
Ga
N
O
CH3
22a  (n = 6) 
22b  (n = 10)
n
OH
HO
(CH2)n
 
 
Scheme 19.  Dimethylgallium Complexes with an Inorganic Tether. 
 
 In an alternative approach, we have designed a receptor ligand in which the gallium is tethered to the 
ligand through an organometallic bond, rather than an inorganic chelate.  We have made good progress on the 
synthesis of this system (Scheme 20), preparing the key dihalide intermediate from which the gallium species 
is to be prepared through a di-Grignard reagent and gallium trichloride.  Work on this system will continue 
under the support of this project but will not be described further in this proposal.   
HO
N
Ga
Me OH
NH2
MeO
NH
MeO
CO2Et
CO2Et
cat. H+
CO2Et
CO2Et
O
N
MeO
Me
Cl
Cl
O
MeO
2. base
3. LiAlH4
1. (EtO)2POCH2CN
2. LiAlH4
3. Li/NH3
4. SOCl2
1. MeI
 
 
Scheme 20. Synthetic Progress Towards a Novel Organometallic Gallium Steroid Mimic 
 
4.b.  Prepare selected fluorine-18 labeled androgens and progestins for imaging prostate and breast 
cancer]  –  
 F-18 Labeled Androgens with for Improved AR Imaging. We have made two analogs of 11β-fluoro-
DHT (17a), a compound that has very high affinity for AR, but appeared to be undergoing rapid metabolism 
in vivo.  These analogs have methyl substitutents at the 7α or the 17α position (18ab), sites at which 
substitution typically increases potency in vivo, presumably by slowing androgen metabolism.  We have 
completed the syntheses of these analogs, and have worked out conditions for their F-18 labeling by a 
bromofluorination-reduction sequence that we have previously reported (not shown).81  They have good 
affinity for the androgen receptor, and their tissue distribution studies will be completed soon. 
 
O
R
F18 OH
H
O
CH3
F OH
H
Y
X
X
H
Me
Y
Me
H
18a
18b
AR (RBA)
36
32
SHBG (RBA)
604
332
(R=CH3)
(R=H)
17a
17b
AR (RBA)
53
75
SHBG (RBA)
1740
134
(R1881=100)      (E2=100)  
 
 We have prepared a number of non-steroidal androgens with halogen labels, some of which we have 
prepared in radiolabeled form and evaluated for their tissue distribution in rats. The structures and binding 
affinities of some of these compounds are shown in Table 3. 
 12
 
John A. Katzenellenbogen 
DE FG02 86ER60401 
 
Table 3: RBA data of non-steroidal AR ligands and standard (R1881). 
Compound RBAa,b
 
1 CF3
O2N
H
N
O
CH3
CH3
 
0.0014 
 
2 CF3
O2N
H
N
O
CH3
H3C OH
 
0.045 ± 0.033 
3 CF3
O2N
H
N
O
H3C OH
Br
 
1.90 ± 0.18 
4 CF3
NC
H
N
O
H3C OH
S
F
O O
 
0.044 ± 0.020 
11 CF3
NC
N
O
CH3
HO
 
0.014 
O
OH
CH3
 
R1881 
100 
a Relative Binding Affinity (RBA) where R1881 is 100%. The Kd value of R1881 is 0.6 nM [32]. 
b Competitive Radiometric Binding Assays were done with purified ligand binding domain of rat 
AR (Panvera/Invitrogen), using [3H]R1881 as tracer, as previously described [33]. 
 
 The synthesis of several of these by different approaches are shown in the schemes below. Two 
approaches to bromoflutamide, one of the highest affinity non-steroidal androgens, are shown in Schemes 21 
and 22. 
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i) Methacryloyl chloride, TEA, CH2Cl2.  ii) Formic acid, H2O2.  THF.  iii) Ammonium Bromide, acetone.
CF3
O2N
NH2
CF3
O2N
H
N
O
CH3
CF3
O2N
H
N
O
H3C OH
Bri
45 % 61 % 95 %
CF3
O2N
H
N
O
CH3
O iiiii
6 7 8 3
 
 
Scheme 21: Synthesis of 3-bromo-hydroxyflutamide from epoxide intermediate (8). 
 
 
O2N
CF3
H
N
O
CH3
O2N
CF3
H
N
O
H3C OH
OH
O2N
CF3
H
N
O
H3C O
O
S
O
O
O2N
CF3
H
N
ii
78%
ii, iii iv
92%50%
7 9 10 3
i) N-methylmorpholine N-oxide, osmium tetroxide, THF.  ii) Thionyl chloride, THF.  iii) NaIO4, RuCl3•3 H2O, CH3CN.  iv) 
NH4Br, Acetone.
O
H3C OH
Br
 
 
Scheme 22: Synthesis of 3-Bromo-hydroxyflutamide from epoxide intermediate 
 
 We also explored a novel non-steroidal antiandrogen and developed an approach to label it with 
fluorine-18. The synthesis is shown in Scheme 23.  The androgen receptor binding affinities of members of 
this series are given in Table 4.  
 
NO2
NO2
N
CH3
CH3
NO2
N
CH3
CH3
NH2
N
H
H
O
O
NO2
N
CH3H3C
N
H
H
O
O
NO2
N
CH3H3C
CH3
N
H
H
O
O
NO2
F
NO2
NH2
OHTf
73 % 51 % 32 %
25 % 35 %
84 %
ii
v
vi
4 5 6
7 8 9
2
i) Benzothiazole-2-sulfenamide, t-BuOK, DMF.  ii) CH3I, NaH, HMPA, THF.  iii) N-Tetramethylenethiocarbamoylsulfenamide, 
t-BuOK, DMF.  iv) cis-5-Norborene-endo-2,3-dicarboxylic anhydride, HOAc.  v) MeOTf, 1,2 Dichloroethane.  vi) TBAF, CH3CN
i iii
iv
 
 
Scheme 23: Synthesis of 3-F-NNDI, a non-steroidal antiandrogen. 
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Table 4: Androgen Receptor Binding Affinities of Non-Steroidal AR Ligands and the Standard, R1881 
(Expressed as Relative Binding Affinity [RBA] values). 
 
Compound RBAa,b
1
N
H
H
O
O
NO2 
0.54 ± 0.48 
2
N
H
H
O
O
NO2
F  
0.20 ± 0.098 
8
N
H
H
O
O
NO2
N
CH3H3C  
<0.004 ± 0.001 
3 CF3
O2N
H
N
O
CH3
OH
CH3
 
0.045 ± 0.033 
O2N
H
N
O
CH3
OH
CH3
 
10 
0.016 ± 0.0021 
O
OH
CH3
 
R1881 
100 
a Relative Binding Affinity (RBA) values are IC50[R1881]/IC50[compound] X 100. By definition, 
R1881 has an RBA value of 100. The Kd value of R1881 is 0.6 nM [5]. 
b Competitive Radiometric Binding Assays were done with purified ligand binding domain of rat 
AR (Panvera/Invitrogen), using [3H]R1881 as tracer, as previously described [31]. 
 
 Bicalutamide is an effective non-steroidal androgen used for endocrine therapy of prostate cancer. We 
have developed a method for isotopic labeling of bicalutamide with F-18. The synthesis of unlabeled material 
is shown in Scheme 24. The radiochemical synthesis, shown in Scheme 25, used a pseudocarrier approach. 
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S
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N
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CH3
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CH3
S
F
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CH3
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i ii iii
89% 31% 87%
(i)  NaH, CH3I, HMPA, THF.  (ii)  MeOTf, CH2Cl2.  
(iii) TBAF, DMSO, 90 °C.  (iv) 14, n-BuLi, THF, -78 °C.
11 12 13 14
CF3
NC
H
N
O
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O
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H
N
O
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S
F
O Oiv
95%
6 1
 
 
Scheme 24: Convergent synthesis of bicalutamide 
 
S
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i
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Scheme 25:  Radiosynthesis of 18F-Bicalutamide 
 
Another interesting analog of bicalutamide is the compounds with a bromine, rather than a fluorine, 
substituent, called, colloquially, bromo-bicalutamide. A synthesis of this material is shown in Scheme 26; the 
synthesis of a thioether analog, reported to have higher binding affinity, is shown in Scheme 27. 
 
S
Br
OO
CH3
i
78%
CF3
NC
H
N
O
H3C OH
S
Br
O O
CF3
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H
N
O
H3C OH
S
Sn(C4H9)3
O O
CF3
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H
N
O
H3C OH
S
Br
O O
ii
28%
iii
(i) nBuLi, 6, THF.  (ii) Hexabutyl ditin, Pd(PPh3)4, TEA, tol.  (iii) NH4Br, 10% HOOAc, HOAc.
84%
18 19
20 19
 
 
Scheme 26: Synthesis of 4-Bromobicalutamide 
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12%
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(i) Methacroyl chloride, TEA, CH2Cl2.  (ii) H2O2, HOCHO. 
(iii)  4-bromo-thiophenol, NaH, THF.  (iv) Hexabutyl ditin, Pd(PPh3)4, tol.  
(v) 1.6% HOOAc / HOAc, NH4Br.  (vi) Diethyl chlorophosphite, CH2Cl2.
25 23
 
 
Scheme 27: Synthesis of 4-Bromo-thiobicalutamide 
 
 We have prepared two F-18 labeled steroidal androgens, 7α-fluoromethyl-5α-dihydrotestosterone and 
7α-fluoromethyl-19-nortestosterone. The syntheses of these two targets are shown in Schemes 28 and 19.  The 
androgen receptor binding affinities of members of this series is given in Table 5. 
 
O
OAc
CN
DiBAL-H
89% 72%
73%
7
OAc
CN
S
S
OMOM
CN
S
S
OH
CN
S
S
OMOM
CHO
S
S
OMOM
CH2OH
S
S
100%
65%
8 9
10 11 12
99%
88%
OMOM
S
S
OAc
OMOM
OAc
O
13 14
OMOM
OH
O
H
OMOM
OMs
O
H
Li0, NH3
62% 82%
15
16
OMOM
F
O
H
17
OH
F
O
H
95%
5 (7α-FM-DHT)
CsF, [bmim][BF4]
7%
HS SH
NaOCH3 MOMCl
NaBH4 Ac2O
Tl(NO3)3•3H2O MsCl
HCl
  
 
Scheme 28: Synthesis of 7α-fluoromethyl-5α-dihydrotestosterone. 
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OH
O
H
OH OMOM
51% 78%
DiBAL-H
85%
18 19 20
21
CN
O
O
CN
O
O
OMOM
CHO
O
O
OMOM
CH2OH
O
O
OMOM
O
O
OMs
22 23
99% 96%
CN
i) CsF, [bmim][BH4]
ii) HCl
11%
OH
O
H
6 (7α-FM-norT)
F
HO OH
MOMCl
NaBH4 MsCl
 
Scheme 29: Synthesis of 7α-fluoromethyl-19-nortestosterone 
 
Table 5: Binding affinities of various steroidal ligands for the AR and SHBG proteins 
 Relative binding affinity (RBA)a
compound AR SHBG 
O
OH
R
H  
   R = H (DHT) 
27 R = CH2OH 
6  R = CH2F 
60 ± 16 
0.17 ± 0.03 
39 ± 7.1 
2125 ± 999 
2.0 ± 0.17 
170 ± 7.1 
O
R1
OH
R2  
   R1 = H, R2 = H (nor-T) 
   R1 = CH3, R2 = H (T) 
5  R1 = H, R2 = CH2F 
18 R1 = H, R2 = CN 
31 ± 1.5 
5.9 ± 1.3 
33 ± 1.6 
1.4 ± 0.30 
30 ± 6.8 
417 ± 88 
7.8 ± 1.3 
0.032 ± .006 
O
H
OH
CH3
 
25 2.5 ± 1.7 1.3 ± 1.1 
O
OH
CH3
 
26 R1881 100 4.0 ± 0.9 
 
aRBA values are the average of 2-3 determinations ± standard deviation.  
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Both of these compounds show promise as agents for imaging androgen receptors in prostate cancer. 
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